Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Endocyte logo — company profile

Endocyte

Founded 1996 United States West Lafayette, United States 16 employees Debt Financing Total: $114.35M Biotechnology, Health Care +1

General Information

Company Name Endocyte
Founded Year 1996
Location United States West Lafayette, United States
Employees 16
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Endocyte. To contact Endocyte, visit endocyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Endocyte compare?

A PDF of Endocyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Endocyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Endocyte

Endocyte is a biopharmaceutical company and a leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Founded in 1996, Endocyte operates within the industries of Biotechnology, Health Care, and Pharmaceutical, with its headquarters located in the United States. The company's last investment was an $8.10M Debt Financing investment at 27 December 2010. The investor information is not provided. Overall, Endocyte's focus on personalized cancer treatment and its advancements in targeted therapies exhibit strong potential for addressing unmet medical needs, making it an intriguing prospect for potential venture capitalist investment.

Business keywords: biopharmaceutical, cancer treatment, targeted therapies, drug conjugation technology, PSMA-targeted radioligand therapy, mCRPC, clinical trials, CAR T-cell therapy, oncology, precision medicine

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $8.10M -
27 Dec 2010
Venture Round $15.00M 2
MidCap Financial
MidCap Financial, Silicon Valley Bank
30 Aug 2010
Series C $26.00M 6
Blue Chip Venture Company Triathlon Medical Venture Partners Burrill & Company
Blue Chip Venture Company, Triathlon Medical Venture Partners +4
19 Jan 2010
Series C $15.00M 6
Blue Chip Venture Company CID Capital Triathlon Medical Venture Partners
Blue Chip Venture Company, CID Capital +4
26 Mar 2007
Venture Round $30.00M 6
Blue Chip Venture Company Triathlon Medical Venture Partners Twilight Venture Partners
Blue Chip Venture Company, Triathlon Medical Venture Partners +4
13 Nov 2006
Series C $12.65M 2
Sanderling Ventures American Bailey Ventures
Sanderling Ventures, American Bailey Ventures
22 May 2003
Series B $7.60M 1
Sanderling Ventures
Sanderling Ventures
10 Jul 2001

Endocyte Alternatives & Competitors

View All Alternatives
Endocyte vs
Anchiano Therapeutics
Anchiano Therapeutics United States

Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat...

Post-IPO Equity
1 employees
Biotechnology, Health Care
Endocyte vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Endocyte vs
Photobiotics
Photobiotics

Innovative solutions for precise MRI imaging and cancer treatment with advanced drug delivery and li...

Venture round
1 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate...
Endocyte was founded in 1996.
Endocyte is headquartered in West Lafayette, United States.
Endocyte operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, cancer treatment, targeted therapies and drug conjugation technology.
Endocyte has approximately 16 employees.
Endocyte has completed 7 funding rounds, raising a total of $114.35M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Endocyte include Anchiano Therapeutics, Prescient Therapeutics, Photobiotics, Lisata Therapeutics, Inc., CIS Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Endocyte and Anchiano Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Endocyte, https://bouncewatch.com/company/endocyte, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout